Peptic ulcer disease

Primary Care - Clinics in Office Practice

Volumn 28, Issue 3, 2001, Pages 487-503

  Smoot, Duane T ^a   Go, Mae F ^b   Cryer, Byron ^c  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH SALICYLATE; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OMEPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CHRONIC DISEASE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG INDUCED DISEASE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER PYLORI; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STOMACH MUCOSA; STRESS; ZOLLINGER ELLISON SYNDROME;

EID: 0034812371     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(05)70049-X     Document Type: Article

References (95)

1. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori, association of specific vacA types with cytotoxin production and peptic ulceration
2. Helicobacter pylori: Comparison of DNA fingerprints provides evidence for intrafamilial infection
3. The cohort effect and Helicobacter pylori
4. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: Risk factors and frequency of complications
5. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group
6. Secretin provocation test in the diagnosis of Zollinger-Ellison syndrome
7. Prevalence of and risk factors for Helicobacter pylori infection in the western part of Germany
8. Cag, a pathogenicity island of Helicobacter pylori, encodes type F-specific and disease-associated virulence factor
9. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers
10. Prevalence of CagA-bearing Helicobacter pylori strains detected by the anti-CagA assay in patients with peptic ulcer disease and in controls
11. Helicobacter pylori infection in recurrent abdominal pain in childhood: Comparison of diagnostic tests and therapy
12. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated
13. Purification and characterization of the vacuolating toxin from Helicobacter pylori
14. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains
15. Peptic ulcer bleeding in the elderly: Relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs
16. Role of Helicobacter pylori serology in evaluating treatment success
17. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection
18. The reliability of urease tests, histology and culture in the diagnosis of campylobacter pylori infection
19. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons
20. Intrafamilial clustering of Helicobacter pylori infection
21. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease
22. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori
23. Isolation of Helicobacter pylori from saliva
24. Identifiable Helicobacter pylori strains or factors important in the development of duodenal ulcer disease
25. Non-human reservoirs of Helicobacter pylori
26. Contributions of genome sequencing to understanding the biology of Helicobacter pylori
27. Effect of antimicrobial therapy on the specific serological response to Helicobacter pylori infection
28. Epidemiology of Campylobacter pylori infection: Ethnic considerations
29. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter pylori
30. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing
31. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States
32. Comparison of rapid serological tests (FlexSure HP and QuickVue) with conventional ELISA for detection of Helicobacter pylori infection
33. Graphical genome comparison: Rearrangements and replication origin of helicobacter pylori [In Process Citation]
34. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced ulcer management
35. Duodenal bicarbonate secretion: Eradication of Helicobacter pylori and duodenal structure and function in humans
36. Current FDA-approved treatments for Helicobacter pylori and the FDA approval process
37. A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates
38. Helicobacter pylori in the drinking water in Peru
39. Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and enteric-coated aspirin
40. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1
41. Antibody to the gastric campylobacter-like organism-clinical correlations and distribution in the normal population
42. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: Is empirical triple therapy justified?
43. Aspirin-induced mucosal injury: Lessons learned from animal models
44. Isolation of Helicobacter pylori in feces from patients in the UK: Confirmation of culture identity by PCR
45. Water source as risk factor for Helicobacter pylori infection in Peruvian children
46. Minimum analysis requirements for the detection of Helicobacter pylori infection by the 13C-urea breath test
47. Functional analysis of putative restriction-modification system genes in the helicobacter pylori J99 genome [In Process Citation]
48. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans
49. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations
50. Randomised comparison of differing durations of twice-a-day triple therapy for eradication of Helicobacter pylori
51. Patient-to-patient transmission of Campylobacter pylori infection by fiberscopic gastroduodenoscopy and biopsy
52. A double-blinded placebo controlled endoscopic study comparing the mucosal injury seen with orally and parenterally administered nonsteroidal analgesic ketorolac tromethamine at therapeutic and supratherapeutic doses
53. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori
54. Capylobacter pylori and duodenal ulcers: The gastrin link
55. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials
56. Do commercial serological kits for Helicobacter pylori infection differ inaccuracy? A meta-analysis
57. Oligomeric and subunit structure of the Helicobacter pylori vacuolating cytotoxin
58. Prevalence of Helicobacter pylori infection in korean children: Inverse relation to socio economic status despite a uniformly high prevalence in adults
59. Identification of Helicobacter pylori DNA in the mouths and stomachs of patients with gastritis using PCR
60. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration
61. Pyloric Campylobacter infection and gastroduodenal disease
62. Rapid urease test in the management of campylobacter pyloridis-associated gastritis
63. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori
64. Effect of ammonia on cell-cycle progression of human gastric cancer cells
65. Demonstration of a phospholipid-rich zone in the human gastric epithelium damaged by Helicobacter pylori
66. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia [see comments]
67. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration
68. Mucin exocytosis: A major target for Helicobacter pylori
69. Diagnostic and therapeutic criteria in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1
70. One week low-dose triple therapy for eradication of H. pylori: A large multicentre, randomised trial
71. Do ulcers burn out or burn on? Managing duodenal ulcer diathesis in the Helicobacter pylori era. Ad Hoc Committee on FDA-Related Matters
72. Iodine-123-Tyr-3-octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by octreotide
73. The incidence of Helicobacter pylori infection
74. Campylobacter pylori antibodies in humans
75. Microdose 14C-urea breath test offers diagnosis of Helicobacter pylori in 10 minutes
76. Pathological significance and molecular characterization of the vacuolating toxin gene of Helicobacter pylori
77. Plasma aspirin esterases in normal individuals, patients, with alcoholic liver disease and rheumatoid arthritis: Characterization and the importance of enzymes components
78. Cure of duodenal ulcers associated with eradication of Helicobacter pylori
79. Campylobacter pylori gastritis not related to periodontal disease
80. Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome
81. Reservoirs of Helicobacter pylori and modes of transmission
82. Evidence for weakening of gastric mucus integrity by Campylobacter pylori
83. Usefulness of culture, histology, and urease testing in the detection of campylobacter pylori
84. A role for culture in diagnosis of helicobacter pylori-related gastric disease
85. Use of autoradiography to assess viability of Helicobacter pylori in water
86. Helicobacter pylori: A cohort Phenomenon
87. [13C]urea breath test to confirm eradication of Helicobacter pylori
88. Mechanism of Helicobacter pylori pathogenesis: Focus on mucus
89. Helicobacter pylori urease activity is toxic to human gastric epithelial cells
90. Adherence of Helicobacter pylori to cultured human gastric epithelial cells
91. Pathogenesis of nonsteroidal anti-inflammatory drug-related upper gastrointestinal toxicity
92. Isolation of Helicobacter pylori from human faeces
93. Diagnosis of Helicobacter pylori infection by HpSA test. European Helicobacter pylori HpSA Study Group
94. In vitro susceptibility of pre-treatment isolates of Helicobacter pylori from two multicenter United States clinical trials
95. A comparison of omeprazole with ranitidine for ulcers associated with nonsteriodal antiinflammatory drugs. Acid suppression Trial: Ranitidine versus Omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group